GLMD - ガルメド・ファ―マシュ―ティカルズ (Galmed Pharmaceuticals Ltd.) ガルメド・ファ―マシュ―ティカルズ

 GLMDのチャート


 GLMDの企業情報

symbol GLMD
会社名 Galmed Pharmaceuticals Ltd. (ガルメド・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC) called aramchol. Its product candidate aramchol is a disease modifying treatment for fatty liver disorders including Non-Alcoholic Steato-hepatitis (NASH). The Company''s Aramchol is a conjugate of cholic acid and arachidic acid which is a member of synthetic Fatty-Acid/Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis (NASH). Aramchol is in Phase IIb clinical trials.   ガルメド・ファ―マシュ―ティカルズはイスラエルの臨床段階のバイオ医薬品会社。肝臓疾患やコレステロ―ル胆石のための一日一回経口療法の新治療薬の開発・商品化に従事。画期的医薬品(ファ―スト・イン・クラス)には、脂肪酸と胆汁酸を結合させた「aramchol」があり、非アルコ―ル脂肪性肝炎などの脂肪管疾患の応用治療となる製品候補を保有する。   
本社所在地 16 Tiomkin Street Tel Aviv 6578317 ISR
代表者氏名 Chaim Hurvitz チャイム・ハービッツ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +972 3-693-8448
設立年月日 41456
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 17人
url www.galmedpharma.com
nasdaq_url https://www.nasdaq.com/symbol/glmd
adr_tso
EBITDA EBITDA(百万ドル) -11.49600
終値(lastsale) 12.32
時価総額(marketcap) 257645129.28
時価総額 時価総額(百万ドル) 241.76590
売上高 売上高(百万ドル) 1.08500
企業価値(EV) 企業価値(EV)(百万ドル) 147.66090
当期純利益 当期純利益(百万ドル) -11.63600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Galmed Pharmaceuticals Ltd revenues remained flat at $538K. Net loss decreased 11% to $5.2M. Revenues reflect market conditions. Lower net loss reflects Research and development expenses decrease of 24% to $3.9M (expense) Financial expenses net increase of 29% to $143K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.48 to -$0.34.

 GLMDのテクニカル分析


 GLMDのニュース

   Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021  2020/12/17 12:00:00 PR Newswire
TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases announced today the addition of an open-label part to its ARMOR Phase 3…
   Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results  2020/11/12 12:00:00 PR Newswire
TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12  2020/11/05 13:30:00 PR Newswire
TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the…
   Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Average Recommendation of “Buy” by Brokerages  2020/10/25 00:28:44 US Banking News
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has earned an average rating of “Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts […]
   Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results  2020/11/12 12:00:00 PR Newswire
TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12  2020/11/05 13:30:00 PR Newswire
TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the…
   Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Average Recommendation of “Buy” by Brokerages  2020/10/25 00:28:44 US Banking News
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has earned an average rating of “Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts […]
   Global Non-Alcoholic Steatohepatitis Management Market 2020:Size, Growth, Industry Trends, Analysis,, Business Opportunities, Emerging Trends By Galmed Pharmaceuticals Ltd, Gemphire Therapeutics, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals  2020/10/23 13:50:47 OpenPR
“Global Non-Alcoholic Steatohepatitis Management Market–Industry Trends and Forecast to 2026” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Non-Alcoholic Steatohepatitis Management market is highly fragmented
   Galmed Pharmaceuticals Reports Third Quarter 2020 Financial Results  2020/11/12 12:00:00 PR Newswire
TEL AVIV, Israel, Nov. 12, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, an oral therapy for the treatment of nonalcoholic…
   The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies  2020/11/10 13:40:14 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 9) Alcon AG (NYSE: ALC ) Aligos Therapeutics Inc (NASDAQ: ALGS ) Aptevo Therapeutics Inc (NASDAQ: APVO ) (announced second complete remission in a patient in Cohort 6 of a Phase 1 study of AVO436 in acute myeloid leukemia and myelodysplastic syndrome patients) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) BIO-TECHNE Corp (NASDAQ: TECH ) BioLife Solutions Inc (NASDAQ: BLFS ) BioNTech SE – ADR (NASDAQ: BNTX ) - announced over 90% efficacy in the Phase 3 study of its coronavirus vaccine candidate co-developed with Pfizer Inc. (NYSE: PFE ) C4 Therapeutics Inc (NASDAQ: CCCC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) (announced positive topline results from Part A of the Phase 3 clinical trial of Nefecon in patients with primary IgA nephropathy) Catalent Inc (NYSE: CTLT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Halozyme Therapeutics, Inc.
   Galmed Pharmaceuticals to Report Third Quarter 2020 Financial Results and Provide Business Update on Thursday November 12  2020/11/05 13:30:00 PR Newswire
TEL AVIV, Israel, Nov. 5, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1 modulator, currently in Phase 3 clinical trial for the…
   Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Given Average Recommendation of “Buy” by Brokerages  2020/10/25 00:28:44 US Banking News
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has earned an average rating of “Buy” from the eleven research firms that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts […]
   Global Non-Alcoholic Steatohepatitis Management Market 2020:Size, Growth, Industry Trends, Analysis,, Business Opportunities, Emerging Trends By Galmed Pharmaceuticals Ltd, Gemphire Therapeutics, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals  2020/10/23 13:50:47 OpenPR
“Global Non-Alcoholic Steatohepatitis Management Market–Industry Trends and Forecast to 2026” New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it.The global Non-Alcoholic Steatohepatitis Management market is highly fragmented

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ガルメド・ファ―マシュ―ティカルズ GLMD Galmed Pharmaceuticals Ltd.)

 twitter  (公式ツイッターやCEOツイッターなど)